chloroquine and derivatives - versus placebo - for COVID-19 prophylaxis pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths 0.98 [0.02, 49.67]< 10%1 study (1/-)50.3 %lownot evaluable highcrucial-
conversion to SARS-CoV- 2–positive status via NP swab 1.10 [0.76, 1.57]< 10%4 studies (4/-)31.0 %some concernnot evaluable moderateimportant-
hospitalization 0.98 [0.06, 15.77]< 10%1 study (1/-)50.5 %lownot evaluable highimportant-
laboratory-confirmed Covid-19 1.10 [0.77, 1.56]< 10%4 studies (4/-)30.0 %some concernnot evaluable moderateimportant-
new illness compatible with Covid-19 0.78 [0.60, 1.01]< 10%3 studies (3/-)96.9 %lownot evaluable highimportant-

safety endpoints 00

serious adverse events 1.04 [0.15, 7.40]< 10%1 study (1/-)48.6 %lownot evaluable highimportant-
adverse events 1.58 [0.75, 3.34]< 195%4 studies (4/-)11.6 %lownot evaluable highnon important-

LoD: level of demonstration ( demonstrated, suggested, inconclusive, safety concerns);
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.